Although Eli Lilly and Co.'s Xigris dorecogin alfa sepsis drug came under surprising and unanticipated criticism at its review by the Anti-Infective Drugs Advisory Committee last week, the FDA has given signs that it is unlikely to pay much attention to the final tally of votes in deciding whether to approve the sepsis compound by its Oct. 27 decision deadline.

Last week's panel meeting broke up in disarray, with the audience confused over how ambiguous votes would be tallied and the company baffled as to how it failed to get a robust endorsement of Xigris.